




**Europe's #1 ecosystem for
cannabinoid & terpene based solutions**



Our Mission

We build Europe's biggest ecosystem for cannabinoid & terpene based solutions and transform ideas into better brands & products for multi-billion markets like pain, sleep & anxiety.




Total Addressable Market (TAM)


Sleep



Pain



Anxiety



...with cumulative sales of **over € 250 billion** for OTC and pharmaceuticals in 2020



We cover with our buy & build strategy the whole value chain and consolidate the strongest players in the industry under one roof.

Medical & D2C Brands

With our medical and D2C portfolio we are acquiring/building profitable brands within our verticals to generate revenue.

We target >50% ownership of our companies.

Production & Biotech

Our production companies convert the innovation generated by R&D into market-ready products.

We target >50% ownership of our companies.

Research & Development

Our R&D portfolio will create new products, formulations and IP and conduct studies to:

- Create innovative products which we are well-positioned to bring to market
- Grow SynBiotic as the leading name and expert in the industry

We execute minority share investments in these companies, in order to get preferential access to the technology.

SynBiotic Accelerator

With our new SynBiotic Accelerator program we incubate

We target >25,1% ownership of our companies with an additional call / put structure up to 100%



We cover with our buy & build strategy the whole value chain and consolidate the strongest players in the industry under one roof.

Medical & D2C Brands



Solidmind Group GmbH
Successful brand-builder in the wellbeing industry
Ownership 100%



Hempamed

Hempamed
(a Solidmind Group GmbH Brand)
One of the Top 3 CBD brands in Germany



BioCBD
(a Solidmind Group GmbH Brand)
One of the biggest marketplace for organic hemp & CBD products



Cannexo GmbH
Joint-venture focus, connecting leading players in the pharma industry
Ownership 50,1%



GECA Pharma GmbH
Import & distribution of medical cannabis products
Ownership 100%

Production & Biotech

LEAN LABS

Lean Labs Pharma GmbH
CBD production & extraction company based in Germany
Ownership 100%



New Venture (in LOI discussion)
Growing cannabinoids in yeast cultures with excellent IP portfolio

Research & Development



GreenLight Pharmaceutical LTD
Platform for clinical trial with cannabinoids
Ownership 25%



NeuroTheryX Canda Ltd
AI-powered drug discovery platform.
Ownership 100%

SynBiotic Accelerator



The Hempany GmbH
Hemp based beverages like "hemi" (hemp milk)
Ownership 25,1%





New Venture (in LOI discussion)
Lifestyle CBD Supplement Brand




New Venture (in LOI discussion)
Lifestyle CBD Cosmetic Brand



We target a growth rate of 75% year by year



SynBiotic Use Of Funds Strategy



Why Cannabinoids & Terpenes?


What are Cannabinoids?

- The hemp plant (*cannabis sativa*) is composed of **more than 120 natural active ingredients**, called cannabinoids
- Many of these 120+ chemical compounds have a positive medical or cosmetic effect
- The two main cannabinoids are delta-9-tetrahydrocannabinol (**THC**) and cannabidiol (**CBD**)
- The remaining vast majority of compounds are still unstudied due to their smaller quantities in the hemp/cannabis plant


What do they do?

- The brain and body communicates through a unique system called the **endocannabinoid system**
- Cannabinoids produce effects by interacting with specific receptors within your central nervous system
- **In easy terms: cannabinoids influence how cells communicate – how they send, receive, or process messages**
- As such, they regulate numerous activities including mood, sleep, memory and appetite

CBD (cannabidiol)




THC (delta-9-tetrahydrocannabinol)






Peer Group Valuation



The graph shows the ratio between the market capitalization to consensus forecast 2021 revenue. Market cap data from 07.05.2021




Shareholder Structure





Stock Performance






Stock Information


WKN:	A2LQ77
ISIN:	DE000A2LQ777
Ticker symbol:	L3D
Stock market location:	Xetra, Düsseldorf, Tradegate, GETTEX
Total number of shares:	2.625.000
Capital stock:	2.625.000,00 EUR
Current Price:	22,00 EUR (26,7 USD)*
Market Cap:	57,8 MEUR (71,4 MUSD)*

* as of the date 07.05.2021 from XETRA



Best-in-class management:

CEO Lars Müller is a successful serial entrepreneur and thought leader



Lars Müller

CEO of SynBiotic SE

Serial Entrepreneur

with > 10 years experience in scaling profitable companies

Founder and CEO of the Solidmind Group GmbH

- Brand builder in the supplement industry with a 40+ remote structured team
- Built one of the most successful CBD Brands in Germany: Hempamed (focusing mainly on hemp-based oils)

In-depth industry know-how from seed to shelf

- Genetics
- Extraction Methods & Analytics
- Product Development

In the cannabinoid business since 2015




A strong core team



Sebastian Stietzel

Chairman of the Supervisory Board

Mr. Stietzel is a serial entrepreneur with a focus on strategy, ops senior leadership coaching. His particular expertise is in post-merger integrations and capital markets fitness. Sebastian has a master's degree in business administration with a focus on IT supported marketing and human resources.



Dr. Marlon Braumann

Member of the Supervisory Board

Dr. Marlon Braumann is a serial entrepreneur and one of the founding partners of European VC fund Elevat3 Capital – an investment fund mainly focused on biotech, medtech, and fintech investments. Alongside this role, Mr. Braumann is also the founder of the global wildlife trust AMES Foundation.



Thomas Hanke

Member of the Supervisory Board

Mr. Hanke is an investor with extensive transaction experience, across private equity, venture capital, growth capital and PIPE transactions. He is well-known for working very closely with his portfolio companies, and has held a number of senior leadership roles.




Portfolio CEOs & Experts



Dr. Le Roy Dowey

CEO Greenlight Pharmaceutical LTD

Following his post-doctoral research, Le Roy became Quality Assurance Officer for Ulster's Biomedical Sciences Research Institute (BMSRI). Le Roy holds a BSc (Hons) in Biochemistry from Queen's University, Belfast and a PhD in Nutritional Biochemistry at Ulster University (2002). Le Roy joined the GreenLight Team in June 2018 and is now CEO.



Dr. James Linden

Founder & Chairman Greenlight Pharmaceutical LTD

As a scientist and a pharma expert, Dr. James Linden has built a world-class research network and the unique ability to aim R&D efforts at the most promising commercial opportunities. James holds a PhD in Biochemistry in the Department of Ophthalmology, Queens University Belfast.



Rainer Seiler

Co-Founder & Shareholder Cannexo Pharma GmbH

Rainer Seiler has many years of leadership experience, including as Managing Director (Zur Rose Gruppe), as General Sales Manager (ratiopharm) and as Director Key Account Management within the pharmaceutical Industry (Rx, OTC, Gx), as well as with wholesalers and mail-order-pharmacy companies.



SynBiotic is backed by renowned investors in the cannabis space




Christian Angermayer



Michael Auerbach

- *Lead Investors* are *Christian Angermayer* and *Michael Auerbach*
- Christian Angermayer is the founder of *Apeiron Investment Group*, his own *family office* focusing on biotech, fintech and deep tech
- Among many other companies, Christian has *founded ATAI Life Sciences AG*, a company focused on developing so-called "psychedelics" for therapeutic purposes
- ATAI has reached approx. *USD 1bn valuation within 2.5 years* since foundation, having *raised more than USD 210 million*
- Michael Auerbach has invested in ATAI in its first financing round in 2018 and continued through all rounds, joining ATAI's board in anticipation of a *2021 IPO of ATAI*
- With his *holding Subversive Capital* Michael is one of the most renowned investors in Cannabis companies worldwide
- *Music industry mogul Jay-Z* joined forces with Michael and Christian and created a *newly formed cannabis company* that's expected to become the largest in California (*OTCQX: SBVCF*)

"Nature heals. With ATAI, we are building the global leader in psychedelics. With SynBiotic, we aim to repeat that success in the European Cannabis market" Christian Angermayer



SynBiotic SE